Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

[1]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[2]  Jianfeng Xu,et al.  Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers , 2007, Genes, chromosomes & cancer.

[3]  Yao-Tseng Chen,et al.  Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.

[4]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[5]  M. Rubin,et al.  Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.

[6]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[7]  J. Brooks,et al.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.

[8]  S. Leung,et al.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.

[9]  L. Klotz,et al.  Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.

[10]  D. Yee,et al.  Disrupting insulin-like growth factor signaling as a potential cancer therapy , 2007, Molecular Cancer Therapeutics.

[11]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[12]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[13]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. , 2006, Genes, chromosomes & cancer.

[14]  A. Seidman.  Systemic treatment of breast cancer. Two decades of progress. , 2006, Oncology.

[15]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[16]  A. Seth,et al.  ETS transcription factors and their emerging roles in human cancer. , 2005, European journal of cancer.

[17]  J. Richie.  Radical prostatectomy vs watchful waiting in early prostate cancer , 2005, BJU international.

[18]  Hans Garmo,et al.  Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer , 2011 .

[19]  Gurkamal Chatta,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy , 2003 .

[20]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[21]  A. Evans,et al.  Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. , 2003, The Canadian journal of urology.

[22]  E. Bergstralh,et al.  Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management , 2001, Cancer.

[23]  R. Hubert,et al.  Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. , 2001, Cancer research.

[24]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[25]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[26]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[27]  J. Hanley,et al.  Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .

[28]  N. Kyprianou,et al.  Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF‐β1 and bcl‐2 expression , 1996, International journal of cancer.

[29]  J. Oesterling,et al.  Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Partin,et al.  Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.

[31]  P. Keane,et al.  Eosinophilic vasculitis (Churg-Strauss syndrome) involving the urethra. , 1994, British journal of urology.

[32]  P. Walsh.  Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.

[33]  B. Wasylyk,et al.  The Ets family of transcription factors. , 1993, European journal of biochemistry.